Kenvue Inc. (NYSE:KVUE), a bio-tech venture, has experienced significant activity recently ranging from
asset management changes to earnings reports and eventful strategic shifts. Parallel Advisors LLC and US Bancorp DE have increased their positions, while TD Asset Management Inc, Orion Portfolio Solutions LLC, and Blackhill Capital Inc have significantly decreased their shares. Furthermore, Ruffer LLP, Assetmark Inc, Clearbridge Investments LLC, D.A. Davidson & CO, TrinityPoint Wealth LLC all made significant acquisitions boosting Kenvue's shareholding, whereas Johnson & Johnson announced a full exit from Kenvue. Despite a
soft earnings report for the first quarter of 2024, and the announcement of a 4% workforce cut, Kenvue shares crossed a 4% yield mark, and upcoming dividends are expected. Analysts have given varying perspectives however Citigroup has maintained a neutral stance on the stock due to
near-term limitations. Kenvue's performance has been labeled
'worst-in-class' by some and is having to deal with job cuts and office closures, while Goldman Sachs still gave sluggish support and declared Kenvue as a profitable and undervalued stock.
Kenvue KVUE News Analytics from Fri, 04 Aug 2023 07:00:00 GMT to Sun, 02 Jun 2024 16:31:10 GMT -
Rating -3
- Innovation -4
- Information 2
- Rumor -2
